Ulla Peen

641 total citations
8 papers, 237 citations indexed

About

Ulla Peen is a scholar working on Reproductive Medicine, Oncology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Ulla Peen has authored 8 papers receiving a total of 237 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Reproductive Medicine, 5 papers in Oncology and 2 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Ulla Peen's work include Ovarian cancer diagnosis and treatment (7 papers), PARP inhibition in cancer therapy (5 papers) and Toxin Mechanisms and Immunotoxins (2 papers). Ulla Peen is often cited by papers focused on Ovarian cancer diagnosis and treatment (7 papers), PARP inhibition in cancer therapy (5 papers) and Toxin Mechanisms and Immunotoxins (2 papers). Ulla Peen collaborates with scholars based in Denmark, United States and Finland. Ulla Peen's co-authors include Sakari Hietanen, Synnöve Staff, Theresa L. Werner, Line Bjørge, Johanna Mäenpää, Gabriel Lindahl, Anja Ør Knudsen, Susanne Malander, Mansoor Raza Mirza and Henrik Roed and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and Annals of Oncology.

In The Last Decade

Ulla Peen

8 papers receiving 228 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ulla Peen Denmark	5	188	151	70	37	29	8	237
Anja Ør Knudsen Denmark	7	215 1.1×	172 1.1×	79 1.1×	40 1.1×	34 1.2×	15	289
María Jesús Rubio-Pérez Spain	6	86 0.5×	80 0.5×	31 0.4×	21 0.6×	15 0.5×	15	137
Mansoor R. Mirza Denmark	5	143 0.8×	79 0.5×	34 0.5×	18 0.5×	19 0.7×	10	168
Lise M. van Wijk Netherlands	4	112 0.6×	96 0.6×	98 1.4×	8 0.2×	37 1.3×	5	192
Marthe M. de Jonge Netherlands	8	133 0.7×	171 1.1×	111 1.6×	10 0.3×	109 3.8×	8	307
Francisca Reyes Turcu United States	2	88 0.5×	31 0.2×	72 1.0×	23 0.6×	19 0.7×	2	140
Christopher Blakeley Spain	8	166 0.9×	112 0.7×	54 0.8×	22 0.6×	113 3.9×	15	210
P.M.L.H. Vencken Netherlands	5	101 0.5×	130 0.9×	71 1.0×	4 0.1×	129 4.4×	6	234
Daliah Tsoref Israel	6	59 0.3×	52 0.3×	66 0.9×	16 0.4×	41 1.4×	15	166
Gregory Ulinski Mexico	3	40 0.2×	132 0.9×	77 1.1×	30 0.8×	86 3.0×	5	219

Countries citing papers authored by Ulla Peen

Since Specialization

Citations

This map shows the geographic impact of Ulla Peen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ulla Peen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ulla Peen more than expected).

Fields of papers citing papers by Ulla Peen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ulla Peen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ulla Peen. The network helps show where Ulla Peen may publish in the future.

Co-authorship network of co-authors of Ulla Peen

This figure shows the co-authorship network connecting the top 25 collaborators of Ulla Peen. A scholar is included among the top collaborators of Ulla Peen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ulla Peen. Ulla Peen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

Fotopoulou, Christina, Jalid Sehouli, Ignace Vergote, et al.. (2022). 2022-RA-276-ESGO Value of surgical cytoreduction for subsequent ovarian cancer relapse in patients previously treated with chemotherapy alone at 1st-relapse: a subanalysis of the DESKTOP III/ENGOT-ov20 trial. International Journal of Gynecological Cancer. 32. A227–A228. 1 indexed citations

Pothuri, Bhavana, Sileny Han, Florian Heitz, et al.. (2020). 810MO Patient-reported outcomes (PROs) in patients (pts) receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial. Annals of Oncology. 31. S612–S613. 5 indexed citations

Mirza, Mansoor Raza, Bente Lund, René dePont Christensen, et al.. (2020). Final survival analysis of NSGO-AVANOVA2/ENGOT-OV24: Combination of niraparib and bevacizumab versus niraparib alone as treatment of recurrent platinum-sensitive ovarian cancer—A randomized controlled chemotherapy-free study.. Journal of Clinical Oncology. 38(15_suppl). 6012–6012. 13 indexed citations

Berg, Tobias, Trine Jakobi Nøttrup, Ulla Peen, & Henrik Roed. (2020). Treatment and outcomes of a Danish ovarian cancer population.. PubMed. 67(1). 2 indexed citations

Mirza, Mansoor Raza, Elisabeth Åvall Lundqvist, Michael J. Birrer, et al.. (2019). Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial. The Lancet Oncology. 20(10). 1409–1419. 187 indexed citations

Mirza, Mansoor Raza, Elisabeth Åvall‐Lundqvist, Michael J. Birrer, et al.. (2019). Combination of niraparib and bevacizumab versus niraparib alone as treatment of recurrent platinum-sensitive ovarian cancer: A randomized controlled chemotherapy-free study—NSGO-AVANOVA2/ENGOT-OV24.. Journal of Clinical Oncology. 37(15_suppl). 5505–5505. 7 indexed citations

Lord, Rosemary, Mansoor Raza Mirza, Linn Woelber, et al.. (2018). Safety and dose modification for patients with low body weight receiving niraparib in the ENGOT-OV16/NOVA phase III trial. Gynecologic Oncology. 149. 11–11. 2 indexed citations

Legarth, Jesper, et al.. (1991). Mifepristone or vacuum aspiration in termination of early pregnancy. European Journal of Obstetrics & Gynecology and Reproductive Biology. 41(2). 91–96. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact